Treatment-Induced Menopause: Why It Hits Differently (and What Nobody Warned You About)
If your body changed suddenly and severely during or after cancer treatment, and nobody sat you down and explained what was actually happening, this post is for you.
Not because I'm going to hand you a neat list of symptoms and tell you to manage them. But because I know what it feels like to have your body become unrecognisable, to have a GP insinuate that your brain fog might be dementia, and to spend years searching for a word that finally made sense of all of it. That word, when I finally found it, was ‘chemopause’. And I hadn't heard it once in the years I'd needed it most.
What Is Treatment-Induced Menopause?
Menopause, in its natural form, is a gradual process. Hormones decline slowly, usually over many years. The body has time to adapt. Symptoms emerge gradually, and while they are often significant, the transition is more of a slow fade than a sudden cut.
Treatment-induced menopause is different. It is abrupt. Chemotherapy, radiation to the pelvic area, surgical removal of the ovaries, and certain hormone-suppressing medications can all trigger menopause suddenly and without warning. Within weeks, or sometimes days, hormone levels that would normally decline over years drop sharply. Your body does not have time to adjust. It doesn't get a runway.
The result is what many women describe as menopause on fast-forward and at full volume.
Why Nobody Warned You This Was Coming
Here is something that struck me when I look back on my own diagnoses, and still does today.
The word "menopause" appears in very few cancer diagnosis conversations. Women are usually told about surgical risks, about the impact of chemotherapy on fertility, and about the need for endocrine therapy afterwards. They are given information about what the treatment will do to the cancer.
They are rarely told what the treatment will do to their hormones. And when they are told, when a clinician does mention early menopause after breast cancer or cancer treatment more broadly, it is often as a footnote. A side effect to manage later. Not a significant physiological event requiring its own informed conversation.
A 2024 Lancet perspective on managing menopause after cancer noted this plainly: globally, nine million women are diagnosed with cancer each year, survival is improving, and more women are living with the long-term effects of cancer treatment, including premature ovarian insufficiency and early menopause. And yet the management of menopausal symptoms in this group remains inconsistent, under-resourced, and often more severe than what women experience at natural menopause.
Most women I speak with did not know that going in. Most women found out the way I did. After the fact, when their body had already changed in ways they didn't expect and couldn't explain.
Menopause After Cancer Treatment: What It Actually Feels Like
I want to be specific here, because I think the language around menopause often sanitises what many women experience. Chemotherapy-induced menopause symptoms, and those triggered by surgery or hormone-suppressing therapy, are not a subtle shift. For many women, they are physically and emotionally destabilising.
The hot flushes and night sweats can be severe. Not a warm flush but a wave of heat that soaks through clothing and sheets, that wakes you several times a night, that makes a professional meeting feel like a physical ordeal. Joint pain can feel disproportionate and confusing, not the quiet ache of ageing but a sharpness and stiffness that makes it hard to get out of bed. The brain fog is real and frightening. I forgot words mid-sentence. Words I had used hundreds of times. A GP suggested we should monitor this, which left me thinking it might be early dementia. I was in my late forties.
There is also the emotional piece, which is less often talked about. The mood changes that come with sudden hormonal disruption are not simply "feeling a bit flat." For many women, they involve significant emotional dysregulation — anxiety, low mood, outbursts that feel foreign, a flatness that sits underneath everything. Survivor's guilt adds another layer. The sense that you survived, so you should feel grateful, so feeling this unwell is somehow ungrateful.
Add to this genitourinary symptoms like pain, vaginal and vulva dryness, recurrent infections and changes to sexual function that often go completely unaddressed. Add in weight gain that can feel inexplicable and unfair, and you begin to understand why women navigating treatment-induced menopause describe feeling like a stranger in their own body. I went from being physically fit and active to feeling, as I have said publicly, like I was in my seventies when I was in my late forties. That is not age. That is hormonal change, happening suddenly, with almost no support.
The Specific Risks That Come With Sudden Hormonal Decline
Natural menopause, when it happens at the expected time in a woman's life, carries its own health implications. Treatment-induced menopause, particularly when it happens before the age of 45, carries additional and specific risks that need to be named clearly.
Bone density. Estrogen plays a critical role in maintaining bone density. When it drops suddenly and significantly, bone loss can accelerate. The two most commonly used endocrine treatments for hormone-sensitive breast cancer — tamoxifen and aromatase inhibitors (AIs) — both affect bone, but in distinct ways, and the difference matters.
Tamoxifen has a complicated relationship with bone. A clinical trial published in the Journal of Clinical Oncology found that in premenopausal women, tamoxifen was associated with measurable bone mineral density loss in the lumbar spine and hip, with an average annual loss of around 1.44% in lumbar bone density over a three-year period. That same treatment was actually protective for bone in postmenopausal women. The impact is not simply about the drug; it is about the hormonal context the woman is already in.
Aromatase inhibitors (AIs) present a more significant and consistent risk. AIs work by suppressing estrogen production almost entirely, which is precisely what makes them effective against hormone-sensitive breast cancer. But that near-complete suppression of estrogen is also what makes them particularly damaging to bone. A 2025 updated joint position statement on AI-associated bone loss, co-authored by the International Osteoporosis Foundation alongside six other leading international organisations, identified that women taking AIs face a two to four times higher risk of bone loss and fractures compared to what occurs in natural menopause. The statement was unambiguous: early bone-protective intervention is essential, not optional.
This is not a minor concern. It is a significant and measurable health risk that begins with treatment and requires active monitoring. Women who experience treatment-induced menopause, particularly those who were premenopausal at diagnosis and go on to take AIs, carry a compounded bone health risk, the sudden loss of estrogen from treatment-induced menopause, followed by the near-total oestrogen suppression of AI therapy, which warrants a baseline assessment and a clear plan from the start, not as an afterthought.
Cardiovascular health. Estrogen has protective effects on the cardiovascular system. Early loss of that protection, including through treatment-induced menopause, is associated with increased cardiovascular risk. The 2024 Lancet perspective on managing menopause after cancer noted that premature ovarian insufficiency (POI), which includes menopause induced by cancer treatment, may increase the long-term risk of chronic conditions, including cardiovascular disease. This is a consideration that rarely makes it into the conversations women have with their oncology or GP teams, and yet it has real implications for long-term health planning. Understanding your cardiovascular baseline before treatment starts, and actively managing lifestyle factors during and after, is not an optional extra. It is part of the picture of living well after cancer.
Metabolic changes. This one is less often spoken about, but it is something many women experience and struggle to explain. The sudden loss of estrogen that comes with treatment-induced menopause can affect how the body processes energy, stores fat, and regulates blood sugar. Weight gain, particularly around the abdomen, changes to cholesterol levels, and shifts in insulin sensitivity are all documented consequences of abrupt hormonal decline, and they can be compounded further by AI therapy. I gained close to 20 kilograms after my treatment. I was fit and active beforehand. People around me didn't understand it, and for a long time, neither did I. It was not about what I was eating or how much I was moving. It was about what my body was doing in the absence of estrogen, without any support to manage that transition. Naming this is important because it affects how women feel about themselves, about their bodies, and about their prospects for recovery. And because it connects directly to cardiovascular risk, the two are not separate conversations.
Cognitive function. The relationship between estrogen and brain function is an active area of research, but what the evidence currently supports is that estrogen plays a role in memory and cognitive processing. Sudden loss of estrogen, not gradual decline, is associated with more pronounced cognitive symptoms. This is one reason brain fog and memory disruption in treatment-induced menopause can be so obvious and so frightening. The good news is that for many women, cognitive symptoms do improve with time and with appropriate support, including, where clinically indicated, hormonal and non-hormonal management. You are not losing your mind. Your brain is responding to a significant hormonal shift, and that is a manageable medical event, not a permanent state.
These are not side effects to wait and see about. They are health considerations that warrant proactive, ongoing attention, and that most women navigating menopause symptoms after cancer treatment have never been told about in this kind of detail.
What I Wish I'd Known to Ask My Doctor Before Treatment Started
This is the section I genuinely wish someone had handed me before I sat down in that consulting room with my Oncologist.
Because so much of what I spent years trying to manage and understand after treatment could have been better understood, or even partially mitigated, if the right conversations had happened before treatment began. Not instead of treatment. Alongside it. As part of a picture of whole-person care that takes quality of life seriously from day one.
If you are at diagnosis, or if you have someone you love who is, these are the questions worth asking.
Can we do a baseline bone density scan now, before treatment begins?
Knowing where your bone density sits before chemotherapy or endocrine therapy starts gives you a reference point. It means that any changes during or after treatment can be measured and responded to, rather than discovered years later when they have already progressed. A baseline DEXA scan is a simple, non-invasive test. It is worth asking for specifically. Don't wait to be offered it.
Am I a good candidate for a baseline cardiovascular risk assessment?
Given what we know about the cardiovascular implications of sudden hormonal decline, understanding your baseline cardiovascular health before treatment starts allows your team to monitor for changes and make informed recommendations about lifestyle and, where relevant, medical management. For some women, this assessment will also flag pre-existing risk factors that can be actively managed during and after treatment.
What lifestyle adjustments should I be thinking about now, to set myself up for recovery?
This question is worth asking before treatment begins, not after. Nutrition, exercise, sleep, and stress management all have a role to play in how well your body moves through treatment and how well it recovers afterwards. This is not about being perfect, or adding pressure to an already overwhelming time. It is about having an informed conversation with your team about what is possible and what is likely to help. A dietitian, an exercise physiologist familiar with cancer care, or a GP who takes an integrative approach to survivorship can all be part of this. The earlier the conversation starts, the more runway you have.
How soon can I start using vaginal estrogen?
This one surprises many women and many clinicians. Local vaginal estrogen, as I discussed in detail in my first post in this series, stays where it is applied. It does not circulate through the body in any meaningful way. The safety data is strong, and there is no good clinical reason for it to be withheld, including for women on endocrine therapy. Starting it early, before genitourinary symptoms become established and severe, makes a genuine difference. If your clinician has not raised it, it is worth raising yourself. Ask directly. Be specific.
I am not a medical professional, and none of this is medical advice. But I know that if someone had sat me down and walked me through these four questions before my treatment started, my experience of the years that followed would have looked very different. You deserve to have these conversations.
What Nobody Warned You About: The Gap in Care
Here is the part that still makes me angry.
For many women, the gap in information and support does not happen only at diagnosis. It happens again at the end of active treatment. When the appointments slow down. When the intensive support of the oncology team disappears, the responsibility for your ongoing health management falls to a GP. A GP who may be experienced and well-intentioned, but who has often received little or no specialist training in menopause, let alone in the specific complexities of treatment-induced menopause after cancer.
This is not a personal failing on the part of GPs. It is a systemic failure. Menopause education in medical training has been, historically, inadequate. The knowledge gap is real and it is well-documented. And for women navigating what is arguably the most complex version of menopause there is, that gap has consequences.
It took me nearly six years to find a GP willing to sit down and have a genuine shared decision-making conversation about my options. Six years of symptoms that affected every part of my life. Six years of being told no, or nothing, or not offered anything beyond an antidepressant for hot flushes.
Six years is not acceptable. And it is not unusual.
But here is what I also know. Things are changing. The evidence base is growing and the expert consensus is moving. More clinicians are engaging with this space than were three years ago. Women are arriving at appointments better informed and more prepared to advocate for themselves. The conversations that didn't exist when I needed them are starting to happen. Not fast enough. Not universally. But they are happening. And every woman who learns what to ask, who walks into an appointment with her questions written down and her voice ready, makes the next conversation a little easier for the woman who comes after her.
The Question Worth Sitting With
If you are reading this and recognising your own experience, I want to say something clearly.
The symptoms you are experiencing are not in your head. The severity is not exaggerated. The impact on your quality of life, your relationships, your work, your sense of self — that is real, and it deserves to be taken seriously.
And there is a way through. Not a perfect path, not an easy one, but a real one. Women who find the right support, who access the right information, who finally get a clinician willing to sit down and have a genuine conversation, they do find their way back to themselves. I did. It took too long and it was harder than it should have been, and I built MACS because I don't want that to be every woman's story.
This is the work I do in 1:1 sessions, with women who are sitting with a fresh diagnosis, trying to understand what is coming and what questions to ask before treatment begins, and with women who are on the other side of treatment, living in a body that changed in ways nobody prepared them for. In both cases, we work through what is actually happening, what options exist, and how to have the conversations with your medical team that you deserve. You don't need to have it all figured out before you reach out. That is exactly what the session is for.
Surviving cancer is not the finish line. Living well is. And living well is possible with the right information and the right support alongside you.
If you're not sure where to start, the free guide is a good first step. It's designed specifically for women navigating life after cancer treatment — what questions to ask, and how to have the conversations your appointments often don't make room for.
If you're ready to talk, I'd love to hear from you. A 1:1 Clarity Session is where we start, whether you're facing treatment or you're already on the other side of it, wondering why nobody told you any of this.
What Comes Next
If you want to understand more about the options available for managing symptoms of treatment-induced menopause, including the evidence around HRT after breast cancer specifically, and what "shared decision-making" actually looks like in practice, I've written about that in detail in my first post in this series.
HRT After Breast Cancer: What's Actually Possible (And the Conversation You Deserve to Have)
The information that exists about managing menopause after cancer treatment is more nuanced than a flat no. Most women navigating this have never been given access to it. That is what I am here to change.
Sonya Lovell is the founder of Menopause After Cancer Support (MACS) and the host of the Dear Menopause podcast. She was diagnosed with breast cancer at 47 and experienced treatment-induced menopause. She is not a medical professional. Nothing in this post constitutes medical advice. Always work with your treating team when making decisions about your care.
References
Hickey M, Szabo RA, Hunter MS. Managing menopause after cancer. The Lancet. 2024. Read the paper
Hickey M, Davies PS, Gorelik A, Goldblatt B, Higgins S, Morrissy S, Marino JL. Treatment of menopausal symptoms in women with or at high risk for breast cancer. The Lancet. 2022. Read the paper
Minnesota Oncology. What You Should Know About Early Menopause as a Cancer Survivor. Read the article
Hadji P, Aapro M, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology. 2025. Read the paper
Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology. 1996. Read the paper
